ClinicalTrials.gg
RecruitingNCT07483099Updated Nov 4, 2026

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

A Phase 2 interventional study of LY4395089 and Mirikizumab - Intravenous (IV) in Crohn Disease, sponsored by Eli Lilly and Company. Recruiting at 71 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 4, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Crohn Disease by Eli Lilly and Company — 6 open to participants now, 7 under way, 4 of them phase 3. Crohn Disease · Eli Lilly and Company.

Planned enrollment
9th of 10
60 · median 171
Started
2026
with 1 other
Phase 2
5 of 10
3 open now
Registered
9th of 10
by date

Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 9th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 10 studies in Crohn Disease by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Crohn Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below:

  • Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs, GLP-1/glucagon (Gcg) RAs, GLP-1/GIP/Gcg RAs, or similar medications for approved indications will be permitted to enroll provided they are on a stable dose at the time of screening

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the exclusion criteria in the IIBD master protocol, except the UC-specific criteria apply, or if any of the following criteria apply:

  • Must not have a hepatic disease
  • Must not have a history of any other bone disease that affects bone metabolism
  • Must not have had any of the following within the past 180 days before screening:

    • acute myocardial infarction
    • cerebrovascular incident
    • hospitalization for unstable angina
    • hospitalization due to congestive heart failure, or
    • coronary revascularization
  • Must not have received or will need any other prohibited medications as specified in the protocol
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Mirikizumab

    Study Period 1: Mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC.

    Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC)

  • Experimental
    LY4395089 and Mirikizumab Co-Administration

    Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC.

    Drug: LY4395089 · Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response

    The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.

    Time frame: Baseline, Up to Week 12

Secondary outcomes

  1. Percentage of Participants who Achieve Clinical Remission

    Time frame: Baseline, Up to Week 12

  2. Percent Change from Baseline in Fecal Calprotectin

    Time frame: Baseline, Up to Week 12

07

Study locations

53 of 71 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 13 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
May 4, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. 19 sites changed recruiting status (18 now recruiting, 1 now suspended)
Show 19 sites
  • Fundação Universidade de Caxias do Sul (FUCS) · Caxias do Sul, BrazilNot yet recruiting→Recruiting
  • Centro de Pesquisa Clínica de Marília - CPCLIM · Marília, BrazilNot yet recruiting→Recruiting
  • CEDOES · Vitória, BrazilNot yet recruiting→Recruiting
  • Studienzentrum MVZ Dachau · Dachau, GermanyNot yet recruiting→Suspended
  • Studiengesellschaft Mitteldeutschland GmbH · Halle, GermanyNot yet recruiting→Recruiting
  • St. Marien- und St. Annastiftskrankenhaus · Ludwigshafen, GermanyNot yet recruiting→Recruiting
  • Twoja Przychodnia PCM · Poznan, PolandNot yet recruiting→Recruiting
  • ETG Siedlce · Siedlce, PolandNot yet recruiting→Recruiting
  • AZ Maria Middelares · Ghent, BelgiumNot yet recruiting→Recruiting
  • UZ Leuven · Leuven, BelgiumNot yet recruiting→Recruiting
  • AZ Delta vzw · Roeselare, BelgiumNot yet recruiting→Recruiting
  • Loema Instituto de Pesquisa Clinica · Campinas, BrazilNot yet recruiting→Recruiting
  • Centro Digestivo de Curitiba · Curitiba, BrazilNot yet recruiting→Recruiting
  • CPCLIN · São Paulo, BrazilNot yet recruiting→Recruiting
  • Semmelweis Egyetem · Budapest, HungaryNot yet recruiting→Recruiting
  • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
  • Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero · Katowice, PolandNot yet recruiting→Recruiting
  • Sonomed Sp. z o. o. · Szczecin, PolandNot yet recruiting→Recruiting
  • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś · Warsaw, PolandNot yet recruiting→Recruiting
Show 2 added (1 Canada, 1 Israel)
  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre · Greenfield Park, Canada
  • Yitzhak Shamir Medical Center · Tsrifin, Israel
Show 1 removed
  • Yitzhak Shamir Medical Center · Ẕerifin, Israel
across 2 updates, Oct 8, 2026 – Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Studienzentrum MVZ Dachau · Dachau, GermanyContact removed (no phone or email listed)
Oct 8, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added, 1 site removed. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • AZ Maria Middelares · Ghent, BelgiumNot yet recruiting→Recruiting
    • UZ Leuven · Leuven, BelgiumNot yet recruiting→Recruiting
    • AZ Delta vzw · Roeselare, BelgiumNot yet recruiting→Recruiting
    • Loema Instituto de Pesquisa Clinica · Campinas, BrazilNot yet recruiting→Recruiting
    • Centro Digestivo de Curitiba · Curitiba, BrazilNot yet recruiting→Recruiting
    • CPCLIN · São Paulo, BrazilNot yet recruiting→Recruiting
    • Semmelweis Egyetem · Budapest, HungaryNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
    • Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero · Katowice, PolandNot yet recruiting→Recruiting
    • Sonomed Sp. z o. o. · Szczecin, PolandNot yet recruiting→Recruiting
    • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś · Warsaw, PolandNot yet recruiting→Recruiting
    Show 2 added (1 Canada, 1 Israel)
    • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre · Greenfield Park, Canada
    • Yitzhak Shamir Medical Center · Tsrifin, Israel
    Show 1 removed
    • Yitzhak Shamir Medical Center · Ẕerifin, Israel
    + 1 other change: verification date
  2. Oct 8, 2026
    8 sites changed recruiting status (7 now recruiting, 1 now suspended)
    Show 8 sites
    • Fundação Universidade de Caxias do Sul (FUCS) · Caxias do Sul, BrazilNot yet recruiting→Recruiting
    • Centro de Pesquisa Clínica de Marília - CPCLIM · Marília, BrazilNot yet recruiting→Recruiting
    • CEDOES · Vitória, BrazilNot yet recruiting→Recruiting
    • Studienzentrum MVZ Dachau · Dachau, GermanyNot yet recruiting→Suspended
    • Studiengesellschaft Mitteldeutschland GmbH · Halle, GermanyNot yet recruiting→Recruiting
    • St. Marien- und St. Annastiftskrankenhaus · Ludwigshafen, GermanyNot yet recruiting→Recruiting
    • Twoja Przychodnia PCM · Poznan, PolandNot yet recruiting→Recruiting
    • ETG Siedlce · Siedlce, PolandNot yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Studienzentrum MVZ Dachau · Dachau, GermanyContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07483099
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
May 4, 2026
Primary completion
Jun 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

There may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or
Contact
clinical_inquiry_hub@lilly.com
1-317-615-4559
Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4395089

Start the discussion